Budesonide And Formoterol Fumarate Dihydrate Aerosol
Product Images NDC 50090-6327

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Budesonide And Formoterol Fumarate Dihydrate (NDC 50090-6327). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Counter Image 15 (308708 Rapihaler Counter 15 (black;130;485))

FDA Label Image

Counter Image 80 (308710 Rapihaler Counter 80 (black;130;485))

FDA Label Image

Figure 1 (Figure1bodytext)

This looks like a table showing results of a treatment involving Budesonide and Formoterol Fumarate Dihydrate. The table shows different dosages and inhalations and their corresponding effectiveness. The treatment may be used for respiratory conditions.*

FDA Label Image

Figure 2 (Figure2bodytext)

FDA Label Image

Figure 3 (Figure3bodytext)

Not available. The text appears to be a combination of various characters and symbols that do not form coherent sentences or meaningful information.*

FDA Label Image

Figure 4 (Figure4bodytext)

This is a graph showing the percent change from baseline in FEV over 12 hours. The x-axis represents the hours, and the y-axis represents the percent change in FEV. The graph has four lines, one labeled Day 1 with Budesonide and Formoterol Fumarate Dihydrate, another labeled Predose O Budesonide, a third labeled FEVY with Formoterol, and the final labeled Final visit (EOT) with Budesonide and Formoterol. The graph also includes a legend explaining the different lines. There is no available information on what study this graph is from or what it represents.*

FDA Label Image

Figure 5 (Figure5bodytext)

FDA Label Image

Figure 6 (Figure6bodytext)

This is a clinical study report for the drug combination of Budesonide and Formoterol Fumarate Dihydrate for inhalation. It includes the measurement of percentage change from baseline in pre-dose FEV. Different dosages of the drug combination, as well as individual dosages of Budesonide and Formoterol, are compared against a placebo. The report includes numerical data and abbreviations for relevant terms.*

FDA Label Image

Figure 7 (Figure7bodytext)

This appears to be a table of data related to the percent change in FEV (forced expiratory volume) from baseline in a study of different treatments for what is likely an obstructive airway disease. The treatments include a combination of Budesonide and Formoterol Fumarate Dihydrate in various doses, as well as separate inhalations of each medication, and a placebo. The duration of treatment is likely six months based on the column heading, and there is an "End of Treatment" row with final data.*

FDA Label Image

Budesonide Structural Formula (Image 01)

FDA Label Image

Structural Fumarate (Image 02)

FDA Label Image

Figure 1 (Image 03)

This appears to be a diagram showing the components of a counter with a mouthpiece connected to a strap. The counter seems to have a canister inside with water and a cover for the mouthpiece.*

FDA Label Image

Figure 2 Gray Arrows (Image 04)

FDA Label Image

Figure 3 (Image 05)

FDA Label Image

Figure 4 (Image 06)

FDA Label Image

Figure 5 (Image 07)

FDA Label Image

Label Image (Lbl500906327)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.